Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic

Br J Haematol. 2020 Aug;190(4):e208-e210. doi: 10.1111/bjh.16985. Epub 2020 Jul 26.

Nadine Farah^{1

2}, Richard Burt^{1

2

3}, Amr R Ibrahim^{1

3}, Robert Baker^{3

4}, Panagiotis D Kottaridis³

¹ HCA Healthcare at UCH, University College Hospitals NHS Foundation Trust, London, UK.
² UCL Cancer Institute, UCL, London, UK.
³ Department of Haematology, University College Hospitals NHS Foundation Trust, London, UK.
⁴ Molecular Pathology, Health Services Laboratories, The Halo Building, London, UK.

No abstract available

Keywords: AML; MRD; acute leukaemia; molecular genetics; molecular haematology.

Publication types